VanEck Pharmaceutical ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
VanEck Pharmaceutical ETF PPH
Morningstar’s Analysis PPH
Will PPH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 71.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 20.75 | 211M | Healthcare |
Merck & Co Inc | 13.36 | 136M | Healthcare |
Novo Nordisk AS ADR | 5.62 | 57M | Healthcare |
Pfizer Inc | 5.18 | 53M | Healthcare |
Bristol-Myers Squibb Co | 4.88 | 50M | Healthcare |
Teva Pharmaceutical Industries Ltd | 4.77 | 49M | Healthcare |
GSK PLC ADR | 4.49 | 46M | Healthcare |
McKesson Corp | 4.34 | 44M | Healthcare |
Cencora Inc | 4.21 | 43M | Healthcare |
Haleon PLC ADR | 3.70 | 38M | Healthcare |